Arcus Biosciences Inc stock is traded at $17.43, with a volume of 1,138,744. It is down -1.91% in the last 24 hours and down -22.57% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Previous Close:
$17.77
Open:
$17.58
24h Volume:
1,138,744
Relative Volume:
0.83
Market Cap:
$2.51B
Revenue:
$236.00M
Net Income/Loss:
-$369.00M
P/E Ratio:
-
EPS:
-$3.18
Net Cash Flow:
-$489.00M
1W Performance:
-4.65%
1M Performance:
-22.57%
6M Performance:
-30.28%
1Y Performance:
-11.93%
1-Day Range:
$17.03$17.72
1-Week Range:
$17.03$19.27
52-Week Range:
$17.03$31.74
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(510) 694-6200Address
3928 POINT EDEN WAY, HAYWARD, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS